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August 16, 2005:730–42emonstrate 9.4% of patients with positive troponin levels and no
AD had a history of congestive heart failure (CHF) as opposed
o 2.7% of troponin-negative and no-CAD patients. A p value is
iven only for comparison across all four subgroups. No statis-
ical comparison is made for the presence of CHF between the
wo subgroups of patients without CAD, nor is multivariate
nalysis available. It is possible that this finding influences the
rognosis in this subgroup, without direct relation to the finding of
levated troponin. The finding of elevated B-type natriuretic
eptide (BNP) as demonstrated in Table 2 (1) in the troponin-
ositive, CAD-negative group supports this contention.
In summary, far larger studies with correction for CHF,
levated BNP, and left ventricular function are necessary to truly
ssess the prognosis of patients with ACS with elevated troponin
nd nonsignificant CAD.
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roponin Levels and
cute Coronary Syndrome
e read with interest the recent study by Dokainish et al. (1).
oth the aim and the result of the study are challenging; this is
ecause the investigators have suggested significant prognostic
vidence for troponin (Tp)-positive patients with acute coronary
yndromes (ACS) but without significant coronary artery disease
CAD). As Dokainish et al. (1) suggested in the Study Limitations
ection, their investigation has disadvantages in being a substudy
ith a limited number of patients and with a limited number of
atients with index event. The main finding of their study—that
o-called false-positive Tp results in patients with ACS but no
ignificant angiographic CAD—begets further attention because
f a higher event rate by means of a composite end point in these
atients. However, this suggestion should be interpreted cau-
iously—as mentioned in the Study Limitations—because angiog-
aphy is not a gold standard for accessing atherosclerosis.
Also, because of the study design it should be remembered that
ll patients were treated by acetylsalicylic acid (ASA), intravenous
eparin, and glycoprotein (GP) IIb/IIIa inhibitor. It is well known
hat patients with an elevated troponin T level and non–ST-
egment elevated ACS (NSTE-ACS) have been reported to
enefit particularly from antithrombotic drugs such as platelet GP
Ib/IIIa antagonists and low-molecular-weight heparin (2). It is
easonable to hypothesize that the elevated troponin T levels in
atients with NSTE-ACS indicate the presence of a thrombus at
ulprit lesions (3). As is known, a culprit lesion responsible for
yocardial infarction is 50% in most cases. Thus, CAD or io-CAD classification by coronary angiography must be ques-
ioned.
Conversely, baseline creatinine (Cr) level differed between the
wo groups (Tp, no-CAD vs. Tp, no-CAD) (0.93  0.56
g/dl, 1.46  2.31 mg/dl, respectively). In the original study,
hronic renal failure (CRF) was an exclusion factor (serum Cr
2.5 mg/dl) (4), but in this substudy the mean Cr is high, and the
tandard deviation is also unexpectedly high. What could be the
xplanation of this high serum Cr in such a study that excludes
atients with CRF? It is well established that patients with CRF
ave higher Tp levels even without any ACS; the difference in Cr
evels may be a consequence of inadequate or slow clearance rather
han excess production due to ACS in this group of patients.
It must be remembered that this study basically compares
o-CAD patients with or without Tp positivity. Hence, two-way
omparisons should be applied instead of four-way comparisons
or statistical analysis. As a result, regarding the small event rate,
he limitations previously mentioned, and our considerations for
he effect of GP IIb/IIIa antagonists in borderline lesions and their
ffect of undiagnosed renal failure, we believe that the conclusion
f the study by Dokainish et al. (1) is quite exaggerated.
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EPLY
e thank Drs. Bybee and Rihal for their valuable comments
egarding our study (1). The major point of our publication is that
atients presenting with symptoms suggestive of acute coronary
yndrome (ACS) who are troponin positive on admission without
vidence of significant epicardial coronary artery disease (CAD) on
ngiography have a worse prognosis than do those who are
roponin negative without significant epicardial disease. In our
iscussion we recognized that the mechanisms conferring this
dverse prognosis are not known. Notwithstanding that, we agree
ith the comments of Drs. Bybee and Rihal that transient left
entricular apical ballooning syndrome (TLVABS) should be
ncluded as a potential explanation for troponin positivity in some
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August 16, 2005:730–42f our patients, especially women. It is intriguing to note that the
nderlying mechanism(s) that account for TLVABS remain un-
nown. Some of the mechanisms, which we suggested in our
tudy, to explain troponin positivity in the absence of significant
picardial coronary disease may be the same ones responsible for
LVABS, namely coronary vasospasm (2), microvascular ischemia
2), acute myocarditis (3), plaque erosions (4), and others such as
motional stress with possible excessive sympathetic stimulation (5).
We would also like to thank Dr. Leibowitz for his interest in
ur study. We agree with his comments that the number of
atients with positive troponin and no significant epicardial coro-
ary disease on angiography is small. Therefore, as we noted in our
tudy Limitations section that “the results should be interpreted
ith caution.”
To validate the results of our study, we have analyzed the event
ate in all patients included in the TACTICS study who were
ither troponin-T or -I positive on admission, and who underwent
oronary angiography either because they were randomized to the
nvasive arm or randomized to the conservative arm and subse-
uently underwent coronary angiography. In this analysis, 57
atients were troponin positive without significant epicardial
AD. Of these patients, one died, two had reinfarction, and four
ere rehospitalized for ACS. Therefore, the composite event rate
as 10.5% at six months compared to no events in the group of
atients who were troponin negative without significant epicardial
isease.
It is worthwhile to mention also that no statistical differences
xisted in the incidence of congestive heart failure or LV ejection
raction between the group of patients without epicardial coronary
isease with or without troponin positivity on admission (2 of 95
atients vs. 3 of 32 patients; p  NS) and (60.5% vs. 58.3%; p 
S), respectively.
In conclusion, large prospective studies are definitely needed to
alidate these potentially important results, which have a signifi-
ant impact on patients presenting with ACS.isham Dokainish, MD
anu Pillai, MD
abina A. Murphy, MPH
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